Dwomoh, L. , Tejeda, G. S. and Tobin, A. B. (2022) Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease. Neuronal Signaling, 6(1), NS20210004. (doi: 10.1042/NS20210004) (PMID:35571495) (PMCID:PMC9069568)
Text
269171.pdf - Published Version Available under License Creative Commons Attribution. 1MB |
Abstract
Alzheimer’s disease (AD) remains a major cause of morbidity and mortality worldwide, and despite extensive research, only a few drugs are available for management of the disease. One strategy has been to upregulate cholinergic neurotransmission to improve cognitive function, but this approach has dose-limiting adverse effects. To avoid these adverse effects, new drugs that target specific receptor subtypes of the cholinergic system are needed, and the M1 subtype of muscarinic acetylcholine receptor (M1-mAChR) has been shown to be a good target for this approach. By using several strategies, M1-mAChR ligands have been developed and trialled in preclinical animal models and in human studies, with varying degrees of success. This article reviews the different approaches to targeting the M1-mAChR in AD and discusses the advantages and limitations of these strategies. The factors to consider in targeting the M1-mAChR in AD are also discussed.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Tejeda, Dr Gonzalo and Tobin, Andrew and Dwomoh, Dr Louis |
Authors: | Dwomoh, L., Tejeda, G. S., and Tobin, A. B. |
College/School: | College of Medical Veterinary and Life Sciences > School of Molecular Biosciences |
Journal Name: | Neuronal Signaling |
Publisher: | Portland Press |
ISSN: | 2059-6553 |
ISSN (Online): | 2059-6553 |
Published Online: | 05 April 2022 |
Copyright Holders: | Copyright © 2022 The Authors |
First Published: | First published in Neuronal Signaling 6(1): NS20210004 |
Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record